Posted by Michael Wonder on 23 Jul 2022
EMA CHMP recommends use of the Moderna COVID-19 booster in adolescents (12-17 Years) in the European Union
22 July 2022 - Moderna today announced that the EMA's CHMP has adopted a positive opinion recommending a variation to the conditional marketing authorisation to include a booster dose of Spikevax, the Company's COVID-19 vaccine, at the 50 µg dose level for adolescents (12-17 years) at least three months after completion of the primary series.
The CHMP based this positive opinion on scientific evidence shared by the company, including comprehensive safety data.
